Advanced search
Publication Cover
Biomarkers in Medicine Volume 3, 2009 - Issue 5
Submit an article Journal homepage
176
Views
1
CrossRef citations to date
0
Altmetric
Theme: Biomarkers: paving the way for better stratification in heart failure - Review

Novel Biomarkers in Heart Failure: An Overview

Jonathan R Dalzell1 British Heart Foundation Cardiovascular Research Centre,University of Glasgow,Glasgow,G12 8TA,UK. Correspondence[email protected]
,
Colette E Jackson1 British Heart Foundation Cardiovascular Research Centre,University of Glasgow,Glasgow,G12 8TA,UK.
,
Theresa A McDonagh2 Department of Cardiology,Royal Brompton Hospital,London,SW3 6NP,UK
&
Roy S Gardner3 Scottish Advanced Heart Failure Service,Golden Jubilee National Hospital,Glasgow,G81 4HX,UK
Pages 453-463 | Published online: 08 Oct 2009

Bibliography

  • Mosterd A , HoesAW: Clinical epidemiology of heart failure.Heart93, 1137–1146 (2007).
  • Gardner RS , ChongKS, McDonaghTA: B-type natriuretic peptides in heart failure.Biomark. Med.1(2), 243–250 (2007).
  • Gegenhuber A , StruckJ, PoelzWet al. : Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP.Clin. Chem.52(5), 827–831 (2006).
  • Elmas E , BrueckmannM, LangSet al. : Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.Int. J. Cardiol.128(2), 244–249 (2008).
  • Gegenhuber A , StruckJ, DieplingerBet al. : Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure.J. Card. Fail.13(1), 42–49 (2007).
  • von Haehling S , JankowskaEA, MorgenthalerNGet al. : Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.J. Am. Coll. Cardiol.50(20), 1973–1980 (2007).
  • Moertl D , BergerR, StruckJet al. : Comparison of midregional pro-ANP and B-type natriuretic peptides in chronic heart failure.J. Am. Coll. Cardiol.53(19), 1783–1790 (2009).
  • Bunton DC , PetrieMC, HillierC, JohnstonF, McMurrayJJ: The clinical relevance of adrenomedullin: a promising profile?Pharmacol. Ther.103(3), 179–201 (2004).
  • Pousset F , MassonF, ChavirovskaiaOet al. : Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure.Eur. Heart J.21(12), 1009–1014 (2000).
  • Morgenthaler NG , StruckJ, AlonsoC, BergmannA: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay.Clin. Chem.51(10), 1823–1829 (2005).
  • Elmas E , LangS, DempfleCEet al. : Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction.Int. J. Cardiol.128(1), 107–111 (2008).
  • Khan SQ , O‘BrienRJ, StruckJet al. : Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.J. Am. Coll. Cardiol.49(14), 1525–1532 (2007).
  • Adlbrecht C , HülsmannM, StrunkGet al. : Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients.Eur. J Heart Fail.11(4), 361–366 (2009).
  • Finley JJ 4th, Konstam MA, Udelson JE: Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation118(4), 410–421 (2008).
  • Goldsmith SR , FrancisGS, CowleyAW Jr, Levine TB, Cohn JN: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol.1(6), 1385–1390 (1983).
  • Morgenthaler NG , StruckJ, AlonsoC, BergmannA: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.Clin. Chem.52(1), 112–119 (2006).
  • Khan SQ , DhillonOS, O‘BrienRJet al. : C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.Circulation115(16), 2103–2110 (2007).
  • Kelly D , SquireIB, KhanSQet al. : C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction.J. Card. Fail.14(9), 739–745 (2008).
  • Voors AA , von HaehlingS, AnkerSDet al.: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.Eur. Heart J.30(10), 1187–1194 (2009).
  • Stoiser B , MörtlD, HülsmannMet al. : Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure.Eur. J. Clin. Invest.36(11), 771–778 (2006).
  • Neuhold S , HuelsmannM, StrunkGet al. : Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.J. Am. Coll. Cardiol.52(4), 266–272 (2008).
  • Helle KB : The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects.Biol. Rev. Camb. Philos. Soc.79(4), 769–794 (2004).
  • Pieroni M , CortiA, TotaBet al. : Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function.Eur. Heart J.28(9), 1117–1127 (2007).
  • Taupenot L , HarperKL, O‘ConnorDT: The chromogranin-secretogranin family.N. Engl. J. Med.348(12), 1134–1149 (2003).
  • Aardal S , HelleKB, ElsayedS, ReedRK, Serck-HanssenG: Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments.J. Neuroendocrinol.5(4), 405–412 (1993).
  • Imbrogno S , AngeloneT, CortiA, AdamoC, HelleKB, TotaB: Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action.Gen. Comp. Endocrinol.139(1), 20–28 (2004).
  • Corti A , MannarinoC, MazzaR, AngeloneT, LonghiR, TotaB: Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7–57 peptide act as cardiostatins on the isolated working frog heart.Gen. Comp. Endocrinol.136(2), 217–224 (2004).
  • Tota B , MazzaR, AngeloneTet al. : Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart.Regul. Pept.114(2–3), 123–130 (2003).
  • Cerra MC , De Iuri L, Angelone T, Corti A, Tota B: Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res. Cardiol.101(1), 43–52 (2006).
  • Angelone T , QuintieriAM, BrarBKet al. : The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.Endocrinology149(10), 4780–4793 (2008).
  • Mazza R , GattusoA, MannarinoCet al. : Catestatin (chromogranin A344–364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart.Am. J Physiol. Heart Circ. Physiol.295(1), H113–H122 (2008).
  • Schulze PC : Chromogranin A: friend or foe of the failing myocardium?Eur. Heart J.28(9), 1052–1053 (2007).
  • Ratti S , CurnisF, LonghiRet al. : Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells.J. Biol. Chem.275(38), 29257–29263 (2000).
  • Soriano JV , PepperMS, TaupenotL, BaderMF, OrciL, MontesanoR: Chromogranin A alters ductal morphogenesis and increases deposition of basement membrane components by mammary epithelial cells in vitro.Biochem. Biophys. Res. Commun.259(3), 563–568 (1999).
  • Ceconi C , FerrariR, BachettiTet al. : Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality.Eur. Heart J.23(12), 967–974 (2002).
  • Dieplinger B , GegenhuberA, StruckJet al. : Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure.Clin. Chim. Acta400(1–2), 91–96 (2009).
  • Boriani G , RegoliF, SaporitoDet al. : Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response.Peptides27(7), 1776–1786 (2006).
  • Wohlschlaeger J , von WinterfeldM, MiltingHet al.: Decreased myocardial chromogranin an expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading. J. Heart Lung Transplant. 27(4), 442–449 (2008).
  • Kleinz MJ , DavenportAP: Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells.Regul. Pept.118, 119–125 (2004).
  • O‘Dowd BF , HeiberM, ChanAet al. : A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.Gene136(1–2), 355–360 (1993).
  • Lee DK , ChengR, NguyenTet al. : Characterization of apelin, the ligand for the APJ receptor.J. Neurochem.74(1), 34–41(2000).
  • Tatemoto K , TakayamaK, ZouMXet al. : The novel peptide apelin lowers blood pressure via a nitric oxide dependent mechanism.Regul. Pept.99, 87–92 (2001).
  • Jia YX , LuZF, ZhangJet al. : Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas.Peptides28, 2023–2029 (2007).
  • Japp AG , CrudenNL, AmerDAet al. : Vascular effects of apelin in vivo in man.J. Am. Coll. Cardiol.52(11), 908–913 (2008).
  • De Mota N , Reaux-Le GoazigoA, El MessariSet al.: Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release.Proc. Natl Acad. Sci. USA101(28), 10464–10469 (2004).
  • Hus-Citharel A , BoubyN, FrugièreA, BodineauL, GascJM, Llorens-CortesC: Effect of apelin on glomerular hemodynamic function in the rat kidney.Kidney Int.74(4), 486–494 (2008).
  • Ernst KV , AshleyEA, CharoDet al. : Apelin regulates cardiac contractility and rescues neurohormonal heart failure.Circulation114 (2006) (Abstract II_66).
  • Szokodi I , TaviP, FoldesGet al. : Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates contractility.Circ. Res.91, 434–400 (2002).
  • Farkasfalvi K , StaggMA, CoppenSRet al. : Direct effects of apelin on cardiomyocyte contractility and electrophysiology.Biochem. Biophys. Res. Comm.357, 889–895 (2007).
  • Jia YX , PanCS, ZhangJet al. : Apelin protects myocardial injury induced by isoproterenol in rats.Regul. Pept.133(1–3), 147–154 (2006).
  • Berry MF , PirolliTJ, JayasankarVet al. : Apelin has in vivo inotropic effects on normal and failing hearts.Circulation110(Suppl. 11), 187–193 (2004).
  • Ashley EA , PowersJ, ChenMet al. : The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.Cardiovasc. Res.65(1), 73–82 (2005).
  • Kuba K , ZhangL, ImaiYet al. : Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload.Circ. Res.101(4), E32–E42 (2007).
  • Weir RA , ChongKS, DalzellJRet al. : Plasma apelin concentration is depressed following acute myocardial infarction in man.Eur. J. Heart Fail.11(6), 551–558 (2009).
  • van Kimmenade RR , JanuzziJL Jr, EllinorPTet al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.J. Am. Coll. Cardiol.48(6), 1217–1224 (2006).
  • Chong KS , GardnerRS, MortonJJ, AshleyEA, McDonaghTA: Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure.Eur. J. Heart Fail.8(4), 355–360 (2006).
  • Chen MM , AshleyEA, DengDXet al. : Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction.Circulation108(12), 1432–1439 (2003).
  • Francia P , SalvatiA, BallaCet al. : Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin.Eur. J. Heart Fail.9(3), 306–309 (2007).
  • Goetze JP , ReCHFeldJF, CarlsenJet al. : Apelin: a new plasma marker of cardiopulmonary disease.Regul. Pept.133(1–3), 134–138 (2006).
  • Földes G , HorkayF, SzokodiIet al. : Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure.Biochem. Biophys. Res. Commun.308(3), 480–485 (2003).
  • Mullens W , BartunekJ, Wilson TangWHet al.: Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients.Heart Rhythm5(1), 52–59 (2008).
  • Burnett JC Jr: Urocortin, advancing the neurohumoral hypothesis of heart failure. Circulation112(23), 3544–3546 (2005).
  • Parkes DG , VaughanJ, RivierJ, ValeW, MayCN: Cardiac inotropic actions of urocortin in conscious sheep.Am. J. Physiol.272(5 Pt 2), H2115–H2122 (1997).
  • Chen ZW , HuangY, YangQ, LiX, WeiW, HeGW: Urocortin-induced relaxation in the human internal mammary artery.Cardiovasc. Res.65(4), 913–920 (2005).
  • Sanz E , MongeL, FernándezNet al. : Relaxation by urocortin of human saphenous veins.Br. J. Pharmacol.136(1), 90–94 (2002).
  • Nishikimi T , MiyataA, HorioTet al. : Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart.Am. J Physiol. Heart Circ. Physiol.279(6), H3031–H3039 (2000).
  • Ikeda K , TojoK, SatoSet al. : Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes.Biochem. Biophys. Res. Commun.250(2), 298–304 (1998).
  • Rademaker MT , CharlesCJ, EspinerEA, FramptonCM, LainchburyJG, RichardsAM: Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure.Eur. Heart J.26(19), 2055–2062 (2005).
  • Rademaker MT , CameronVA, CharlesCJ, RichardsAM: Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.Circulation112(23), 3624–3632 (2005).
  • Rademaker MT , CameronVA, CharlesCJ, RichardsAM: Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure.Eur. Heart J.27(17), 2088–2098 (2006).
  • Bale TL , HoshijimaM, GuYet al. : The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure.Proc. Natl Acad. Sci. USA101(10), 3697–3702 (2004).
  • Rademaker MT , CharlesCJ, RichardsAM: Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure.Am. J. Physiol. Heart Circ. Physiol.293(3), H1536–H1544 (2007).
  • Ng LL , LokeIW, O‘BrienRJ, SquireIB, DaviesJE: Plasma urocortin in human systolic heart failure.Clin. Sci.106(4), 383–388 (2004).
  • Crane FL , HatefiY, LesterRL, WidmerC: Isolation of a quinone from beef heart mitochondria.Biochim. Biophys. Acta25(1), 220–221 (1957).
  • Folkers K , VadhanavikitS, MortensenSA: Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10.Proc. Natl Acad. Sci. USA82(3), 901–904 (1985).
  • Molyneux SL , FlorkowskiCM, GeorgePMet al. : Coenzyme Q10: an independent predictor of mortality in chronic heart failure.J. Am. Coll. Cardiol.52(18), 1435–1441 (2008).
  • Sander S , ColemanCI, PatelAA, KlugerJ, WhiteCM: The impact of coenzyme Q10 on systolic function in patients with chronic heart failure.J. Card. Fail.12(6), 464–472 (2006).
  • Mortensen SA : Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of “Q-symbio” – a multinational trial.Biofactors18(1–4), 79–89 (2003).
  • Hopkins TA , OuchiN, ShibataR, WalshK: Adiponectin actions in the cardiovascular system.Cardiovasc. Res.74(1), 11–18 (2007).
  • Fujioka D , KawabataK, SaitoYet al. : Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart.Am. J Physiol. Heart Circ. Physiol.290(6), H2409–H2416 (2006).
  • Dieplinger B , GegenhuberA, PoelzW, HaltmayerM, MuellerT: Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure.Clin. Biochem.42(10–11), 1190–1193(2009).
  • Tanaka T , TsutamotoT, SakaiHet al. : Effect of atrial natriuretic peptide on adiponectin in patients with heart failure.Eur. J. Heart Fail.10(4), 360–366 (2008).
  • Kistorp C , FaberJ, GalatiusSet al. : Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.Circulation112(12), 1756–1762 (2005).
  • McEntegart MB , AwedeB, PetrieMCet al. : Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide.Eur. Heart J.28(7), 829–835 (2007).
  • Schaap FG , van der Vusse GJ, Glatz JF: Fatty acid-binding proteins in the heart. Mol. Cell. Biochem.180(1–2), 43–51 (1998).
  • Setsuta K , SeinoY, OgawaT, AraoM, MiyatakeY, TakanoT: Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure.Am. J. Med.113(9), 717–722 (2002).
  • Niizeki T , TakeishiY, ArimotoTet al. : Serum heart-type fatty acid binding protein predicts cardiac events in elderly patients with chronic heart failure.J. Cardiol.46(1), 9–15 (2005).
  • Komamura K , SasakiT, HanataniAet al. : Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy.Heart92(5), 615–618 (2006).
  • Niizeki T , TakeishiY, ArimotoTet al. : Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure.Circ. J.69(8), 922–927 (2005).
  • Niizeki T , TakeishiY, ArimotoTet al. : Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients.J. Card. Fail.13(2), 120–127 (2007).
  • Niizeki T , TakeishiY, ArimotoTet al. : Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure.Circ. J.72(1), 109–114 (2008).
  • Hansen MS , StantonEB, GawadYet al. : Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.Am. J. Cardiol.90(9), 969–973 (2002).
  • Sugiura T , TakaseH, ToriyamaT, GotoT, UedaR, DohiY: Circulating levels of myocardial proteins predict future deterioration of congestive heart failure.J. Card. Fail.11(7), 504–509 (2005).
  • Mann DL : Inflammatory mediators and the failing heart: past, present, and the foreseeable future.Circ. Res.91(11), 988–998 (2002).
  • Yanagisawa K , TsukamotoT, TakagiT, TominagaS: Murine ST2 gene is a member of the primary response gene family induced by growth factors.FEBS Lett.302(1), 51–53 (1992).
  • Townsend MJ , FallonPG, MatthewsDJ, JolinHE, McKenzieAN: T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses.J. Exp. Med.191(6), 1069–1076 (2000).
  • Weinberg EO , ShimpoM, De KeulenaerGWet al.: Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.Circulation106(23), 2961–2966 (2002).
  • Schmitz J , OwyangA, OldhamEet al. : IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.Immunity.23(5), 479–490 (2005).
  • Sanada S , HakunoD, HigginsLJ, SchreiterER, McKenzieAN, LeeRT: IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.J. Clin. Invest.117(6), 1538–1549 (2007).
  • Sabatine MS , MorrowDA, HigginsLJet al. : Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.Circulation117(15), 1936–1944 (2008).
  • Boisot S , BeedeJ, IsaksonSet al. : Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.J. Card. Fail.14(9), 732–738 (2008).
  • Rehman SU , MuellerT, JanuzziJL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol.52(18), 1458–1465 (2008).
  • Januzzi JL Jr, PeacockWF, MaiselASet al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.J. Am. Coll. Cardiol.50(7), 607–613 (2007).
  • Mueller T , DieplingerB, GegenhuberA, PoelzW, PacherR, HaltmayerM: Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.Clin. Chem.54(4), 752–756 (2008).
  • Weinberg EO , ShimpoM, HurwitzS, TominagaS, RouleauJL, LeeRT: Identification of serum soluble ST2 receptor as a novel heart failure biomarker.Circulation107(5), 721–726 (2003).
  • Kempf T , EdenM, StrelauJet al. : The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury.Circ. Res.98(3), 351–360 (2006).
  • Xu J , KimballTR, LorenzJNet al. : GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation.Circ. Res.98(3), 342–350 (2006).
  • Kempf T , von HaehlingS, PeterTet al.: Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.J. Am. Coll. Cardiol.50(11), 1054–1060 (2007).
  • Garlanda C , BottazziB, BastoneA, MantovaniA: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition and female fertility.Annu. Rev. Immunol.23, 337–366 (2005).
  • Latini R , MaggioniAP, PeriGet al. : Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.Circulation110(16), 2349–2354 (2004).
  • Suzuki S , TakeishiY, NiizekiTet al. : Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.Am. Heart J.155(1), 75–81 (2008).
  • Kotooka N , InoueT, AokiS, AnanM, KomodaH, NodeK: Prognostic value of pentraxin 3 in patients with chronic heart failure.Int. J. Cardiol.130(1), 19–22 (2008).
  • Xie Z , PimentalDR, LohanSet al. : Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species.J. Cell. Physiol.188, 132–138 (2001).
  • Singh K , SirokmanG, CommunalCet al. : Myocardial osteopontin expression coincides with the development of heart failure.Hypertension33(2), 663–670 (1999).
  • Xie Z , SinghM, SinghK: Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice.Hypertension44(6), 826–831 (2004).
  • Kramer F , SandnerP, KleinM, KrahnT: Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat.Biomarkers13(3), 270–281 (2008).
  • Stawowy P , BlaschkeF, PfautschPet al. : Increased myocardial expression of osteopontin in patients with advanced heart failure.Eur. J. Heart Fail.4(2), 139–146 (2002).
  • Satoh M , NakamuraM, AkatsuT, ShimodaY, SegawaI, HiramoriK: Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy.Eur. J. Heart Fail.7(5), 755–762 (2005).
  • Rosenberg M , ZugckC, NellesMet al. : Osteopontin, a new prognostic biomarker in patients with chronic heart failure.Circ. Heart Fail.15(4), 43–49 (2008).
  • Marathe S , SchisselSL, YellinMJet al. : Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling.J. Biol. Chem.273(7), 4081–4088 (1998).
  • Hernandez OM , DischerDJ, BishopricNH, WebsterKA: Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes.Circ. Res.86(2), 198–204 (2000).
  • Oral H , DornGW 2nd, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J. Biol. Chem.272(8), 4836–4842 (1997).
  • Doehner W , BunckAC, RauchhausMet al. : Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow.Eur. Heart J.28(7), 821–828 (2007).
  • Pennica D , SwansonTA, ShawKJet al. : Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization.Cytokine8(3), 183–189 (1996).
  • Pemberton CJ , RaudseppSD, YandleTG, CameronVA, RichardsAM: Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch.Cardiovasc. Res.68(1), 109–117 (2005).
  • Zolk O , EngmannS, MünzelF, KrajcikR: Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue.Am. J. Physiol. Endocrinol. Metab.288(6), E1214–E1221 (2005).
  • Jin H , YangR, KellerGAet al. : In vivo effects of cardiotrophin-1.Cytokine8(12), 920–926 (1996).
  • Tsutamoto T , WadaA, MaedaKet al. : Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy.J. Am. Coll. Cardiol.38(5), 1485–1490 (2001).
  • Tsutamoto T , AsaiS, TanakaTet al. : Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure.Eur. J. Heart Fail.9(10), 1032–1037 (2007).
  • Li Y , Komai-KomaM, GilchristDSet al. : Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation.J. Immunol.181(4), 2781–2789 (2008).
  • Sharma UC , PokharelS, van BrakelTJet al.: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation110(19), 3121–3128 (2004).
  • Sharma U , RhalebNE, PokharelSet al. : Novel anti-inflammatory mechanisms of N-acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.Am. J Physiol. Heart Circ. Physiol.294(3), H1226–H1232 (2008).
  • Milting H , EllinghausP, SeewaldMet al. : Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.J. Heart Lung Transplant.27(6), 589–596 (2008).
  • Abrahamson M , OlafssonI, PalsdottirAet al. : Structure and expression of the human cystatin C gene.Biochem. J.268(2), 287–294 (1990).
  • Lassus J , HarjolaVP, SundRet al. : Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.Eur. Heart J.28(15), 1841–1847 (2007).
  • Ix JH , ShlipakMG, ChertowGM, WhooleyMA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.Circulation115(2), 173–179 (2007).
  • Arimoto T , TakeishiY, NiizekiTet al. : Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure.J. Card. Fail.11(8), 595–601 (2005).
  • Shlipak MG , KatzR, FriedLFet al. : Cystatin-C and mortality in elderly persons with heart failure.J. Am. Coll. Cardiol.45(2), 268–271 (2005).
  • De Pasquale CG : Surfactant protein-B in chronic heart failure: an insight to the alveolocapillary barrier.Rev. Esp. Cardiol.62(2), 117–119 (2009).
  • De Pasquale CG , ArnoldaLF, DoyleIR, GrantRL, AylwardPE, BerstenAD: Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema.Crit. Care Med.31(4), 1060–1067 (2003).
  • De Pasquale CG , ArnoldaLF, DoyleIR, AylwardPE, ChewDP, BerstenAD: Plasma surfactant protein-B: a novel biomarker in chronic heart failure.Circulation110(9), 1091–1096 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.